Therapeutic Approach

Category: Uncategorized

Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28

Patent covers methods for treating symptoms associated with lactose intolerance and improving gastrointestinal health LOS ANGELES (June 28, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it recently has been issued […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update

LOS ANGELES (March 21, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutics that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the fourth quarter and full year ended December 31, 2015. 2015 and Recent Operational […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD